New Biologix develops engineered cell line technology for producing AAV drugs for gene therapy, focusing on making treatments more affordable and accessible.

New Biologix

NewBiologix | 2,623 followers on LinkedIn. Developing technologies for the biopharma industry to allow them 
to treat the root causes of diseases and disorders. | Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies.

Chief Digital Officer

Thierry Schuepbach

CFO || Executive Finance Specialist || Facilitator || Startup & Board Advisor || Global || IPMA ||

Tatjana Bauecker, MBA

Senior R&D Director Bioinformatics, NewBiologixSA

Romain Daveau

VP of R&D

Efrain Guzman

NewBiologix

Introducing the Xcell™ Portfolio from NewBiologix—a comprehensive suite of advanced technologies designed to power next-generation gene and cell therapies. Designed with Swiss-precision and flexibility, Xcell™ offers a robust foundation for developing and manufacturing reliable gene therapies. Discover the future of gene therapy innovation. Learn more here >> https://lnkd.in/eDp6ntwn #GeneTherapy #BiotechInnovation #XcellPortfolio

📢 In case you missed it! With gene therapy costs often exceeding $4 million per dose, there's an urgent need for breakthroughs in manufacturing to make these treatments more accessible. In a recent feature with Endpoints News , our CEO, Igor Fisch , discusses how NewBiologix's Xcell™ Portfolio is transforming gene therapy production. By replacing traditional methods with stable cell lines, we aim to streamline rAAV production, improving yield consistency and lowering costs. Read more about our mission: https://lnkd.in/e8X2y_YM #NewBiologix #GeneTherapy #Innovation

The #NewBiologix team is having a wonderful time at BIO-Europe! As we continue to push boundaries in gene therapy and biotech, we’re excited to share insights, explore partnerships and engage in meaningful discussions with industry peers. If you’re attending, let’s connect and discuss how partnering with us can help advance gene therapies to improve scalability, lower production costs and accelerate affordable patient access. We look forward to the rest of the week! #BIOEurope #Innovation #GeneTherapy

The high cost of #GeneTherapies , which can reach more than $4 million per dose, highlights the need for manufacturing solutions that can deliver these life-saving treatments to patients more affordably and at scale. At NewBiologix, we're leading the way with our Xcell™ Portfolio, a suite of technologies to streamline rAAV production, improve yield consistency and lower costs. Our CEO, Igor Fisch , Ph.D., discusses these challenges and our innovative solutions in a recent article featured in Endpoints News . By developing stable cell lines to replace transient transfection methods, we’re tackling cost, scalability, and regulatory hurdles, making gene therapies more accessible. Read more: https://lnkd.in/edjeqEK4 . #NewBiologix

#NewBiologix is proud to launch the Xcell™ Portfolio, a suite of advanced services and engineered cell lines that address the biggest challenges in viral vector manufacturing—low yields, batch inconsistencies, scalability issues, and high costs. Xcell includes: - Xcell™ Eng-HEK293 Cell Line: High-performance HEK293 line optimized for transient rAAV production. - Xcell™ rAAV Production & Testing Platform: Streamlined solution for efficient rAAV candidate production and testing. - Xcell™ Genomic Analytical Platform: Custom sequencing and bioinformatics solutions for comprehensive rAAV analysis. With our proprietary HEK293-based technology and decades of expertise, we enable our partners in research, #biotech , and pharma to develop safer and more effective gene therapies at scale. Read the full press release for more details: https://lnkd.in/eiKuvxWj

#NewBiologix CEO & Co-Founder Igor Fisch and Chief Operating Officer Déborah Ley are headed to Biotechnology Innovation Organization -Europe in Stockholm, Sweden, from November 4–6, 2024! NewBiologix is committed to helping partners advance the treatment of rare, chronic, and incurable diseases by closing the innovation gap in economically viable, large-scale viral vector production for gene therapy. Let's connect and explore how we can drive this mission forward together—reach out to request a meeting! #BIOEurope #Innovation #GeneTherapy

According to data presented at the 2024 Cell & Gene Meeting on the Mesa, the cell and gene therapy industry is beginning to recover from recent investment challenges, with $10.9 billion raised in the first half of this year. While smaller, preclinical-stage companies have faced difficulties securing funding, there is renewed optimism for the future. With increasing investments in cell and gene therapy, we are excited about the opportunity to help our partners develop life-changing innovations and offer hope for improved quality of life to patients. Read more 👉 https://bit.ly/3UtH2Ur

#NewBiologix is on the ground at the European Society of Gene and Cell Therapy Annual Meeting in Rome! We've had a productive week engaging in lively discussions, cutting-edge research presentations, and collaborative exchanges with top scientific leaders in #GeneTherapy . Please reach out to Efrain Guzman , Luca Nanni , or Pelin Kolçak Yaşlı, Ph.D. , to continue discussions about how NewBiologix can help you revolutionize the field of gene therapy! #ESGCT2024

We are excited to announce that two of our abstracts have been selected for poster presentations at the 31st Annual European Society of Gene and Cell Therapy Congress (ESGCT)! Our presentations will highlight our innovative #CellLine technologies designed to overcome the traditional limitations of #GeneTherapy production. Presentation Details: Generation and Characterization of a HEK293 Cell Line for rAAV production October 22 | 19:30 - 21:00 CEST | P0039 An Integrated Platform for the Analysis and Quality Control of rAAV Vectors Based on Long-read Sequencing October 23 | 13:30 - 15:00 CEST | P0174 Join us in Rome to explore how we’re advancing the future of gene therapy! #NewBiologix #ESGCT2024

Press Release: NewBiologix has been selected for two poster presentations at the 31st Annual European Society for Gene & Cell Therapy Congress (ESGCT), taking place October 22-25, 2024, at La Nuvola in Rome, Italy. Pelin Kolçak Yaşlı, Ph.D. to present Oct. 22 at 19:30 and Luca Nanni on Oct. 23 at 13:30. Learn More about the presentations here >> https://bit.ly/3UddSsx

news impact assignment basic	general
public peers	general	Nov 19, 2024 4:36 AM	3ca35534
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 4:36 AM	ec49429e
crunchbase trigger	general	Nov 19, 2024 4:36 AM	978d07f1
crunchbase profile	general	Nov 19, 2024 9:49 PM	205d1250
li profile	general	Nov 19, 2024 4:36 AM	1388aa88
translate crunchbase fundingrounds	general
peers	general	Nov 19, 2024 4:36 AM	68dc26af
news basic	general	Nov 19, 2024 4:36 AM	9095d118
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

NEWB

COM:NEWBIOLOGIX

New Biologix